3rd Quarter - Report

ROCK & ASSOCIATES for US COMPOUNDING

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$11,250
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 13, 2015 $11,250 Replaced
3rd Quarter - Amendment Oct 13, 2015 — Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Appropriations to fund the FDA implementation of compounding pharmacy regulations.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Law Enforcement/Crime/Criminal Justice LAW

Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1406 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.